Table 2.

Effects of agonists injected into the RVLM on LF:HF HR

	Δ LF:HF HR
	Pre‐F13A	Post‐F13A
Saline	0.05 ± 0.03	−0.02 ± 0.01
[Pyr1]apelin‐13	0.73 ± 0.33*	−0.05 ± 0.04†
	Pre‐losartan	Post‐losartan
Saline	0.01 ± 0.01	−0.03 ± 0.03
[Pyr1]apelin‐13	0.37 ± 0.15*	0.27 ± 0.10
Ang II	−0.17 ± 0.05**	−0.01 ± 0.01‡‡
	Pre‐SR 49059	Post‐SR 49059
Saline	−0.04 ± 0.03	−0.02 ± 0.01
DMSO	0.02 ± 0.02	−0.01 ± 0.02
[Pyr1]apelin‐13	0.38 ± 0.11***, +++	0.01 ± 0.01†††
VP	0.26 ± 0.07**, +	−0.02 ± 0.01‡‡
	Pre‐dOVT	Post‐dOVT
Saline	0.01 ± 0.01	−0.02 ± 0.03
[Pyr1]apelin‐13	0.49 ± 0.15*	0.52 ± 0.13**
OT	0.38 ± 0.18	0.07 ± 0.04
	Pre‐kynurenic acid	Post‐kynurenic acid
Saline	0.02 ± 0.02	−0.01 ± 0.01
[Pyr1]apelin‐13	0.17 ± 0.03*	0.15 ± 0.04**
Glutamate	0.42 ± 0.11*	0.02 ± 0.10‡
	Pre‐bicuculline	Post‐bicuculline
Saline	0.02 ± 0.01	−0.02 ± 0.02
[Pyr1]apelin‐13	0.12 ± 0.01	0.17 ± 0.04*
Muscimol	0.14 ± 0.04*	−0.02 ± 0.04‡‡

^* P < 0.05, ^** P < 0.01, ^*** P < 0.001 vs. saline. ⁺ P < 0.05, ⁺⁺ P < 0.01, ⁺⁺⁺ P < 0.001 vs. DMSO. ^† P < 0.05, ^†† P < 0.01, ^††† P < 0.001 [Pyr¹]apelin‐13 pre‐ vs. [Pyr¹]apelin‐13 post‐antagonist. ^‡ P < 0.05, ^‡‡ P < 0.01, ^‡‡‡ P < 0.001 Agonist pre‐ vs. agonist post‐antagonist.